BioNTech, Nel ASA and Desert Gold - Ripe for uptrend?

Desert Gold: Exciting explorer for less than CAD 10 million

The gold chart gives investors hope. The strong US dollar and rising interest rates are priced in now. In addition, there is hope that we are not far from the top on both. With a view to an impending recession, interest rates could even fall again in the coming year. And the stock market likes to anticipate the future. Accordingly, the current double bottom could be at USD 1,615. Thus, Goldman Sachs sees a significantly greater chance of gold rising above USD 2,000. Even if interest rates continue to rise significantly, they still see gold at USD 1,500.

This should also mean that the worst is over for mining stocks like Barrick Gold. Those who want to "leverage" the gold price more strongly are turning to explorers such as Desert Gold. The share has lost 35% of its value in the past six months and is now trading at just CAD 0.065. Although operationally, everything is going according to plan. Nevertheless, the Canadians are now valued at less than CAD 10 million. Desert Gold owns one of the largest non-producing land areas in West Africa with the 440 sq km SMSZ project. Barrick Gold, Allied Gold, Endeavour Mining and B2Gold, among others, are already producing in the neighborhood. The Desert Gold project includes measured and indicated mineral resources of nearly 1.1 million ounces. Samples from the Mogoyafara South projection area have recovered between 86% and 88% of the gold from the rock. The next drill program is expected to delineate resources in the Mogoyafara South and Gourbassi West North areas. It is here that the Company expects to find the largest gold deposits. Anyone curious should watch the board presentation from the IIF virtual investor conference (here).

Nel: ITM Power shocks investors

Shareholders of hydrogen companies also need strong nerves at the moment. Yesterday, ITM Power again caused shock waves throughout the industry with a profit warning. ITM reported a series of manufacturing problems and delays in tool production and test runs. Accordingly, the share price plummeted by a good 30% yesterday. Nel also lost significantly at first but was able to limit the losses to less than 2% at the close of trading. However, this means the upward trend of the past few days has come to an end for the time being. Despite weak quarterly figures and negative analyst comments, the shares of the Norwegian company were able to gain recently. Investors are clinging to the high order backlog - this does not apply to analysts. Although the high order backlog makes hope for the year 2024 in the view of JPMorgan, for the current and next year, the sales expectations have been scaled back for the time being. Accordingly, JPMorgan rates the Nel share as "Underweight" with a price target of NOK 10. Currently, the share is trading just above NOK 12.

BioNTech: USD 183 or USD 312? Analysts disagree

The BioNTech share currently needs more big impulses. The stock has been trading in a range between EUR 120 and EUR 160 for months. According to Berenberg, significantly higher prices could be possible. Although there is still uncertainty as to how the revenues from the Corona vaccine could continue in the coming year, there is an interesting development in the US. BioNTech partner Pfizer has indicated that it will quadruple the price of the Corona vaccine in the US. This could serve as a model for Europe and would enable BioNTech to generate decent revenues even for smaller quantities. Looking at the development pipeline, the analysts remain positive in the long term. Therefore, Berenberg recommends BioNTech shares as a buy and states a price target of USD 312. JPMorgan is considerably more cautious. The analysts of the US bank have reduced the price target from USD 183 to USD 132. In their view, there is great uncertainty in the sales forecast for the coming years. Only with further progress in the immuno-oncology pipeline does the share have above-average development potential again.

BioNTech is simply lacking momentum at the moment. There is almost only bad operating news coming out of the hydrogen sector at present. The bright long-term prospects for Nel & Co. can only help to a limited extent. The worst could be over for gold. After the double bottom, the bulls are taking courage again. Desert Gold could profit disproportionately from this. Thus, the share seems anything but expensive.